期刊文献+

高敏C反应蛋白血清BNP水平与心衰程度关系的研究 被引量:4

Study of association between high sensitivity C-reactive protein blood-serum BNP levels and congestive heart failure degree
原文传递
导出
摘要 目的观察心衰患者血清B型钠利尿肽(BNP)、高敏C反应蛋白(hsCRP)的水平变化,研究BNP、hsCRP与心功能状况之间的关系。方法本研究选择心力衰竭患者50例,正常对照45例,观察其BNP和hsCRP的变化。结果心衰患者的BNP和hsCRP较对照组明显升高,随着心功能状态的恶化,BNP和hsCRP逐渐升高,且心力衰竭越重,BNP和hsCRP水平越高,两组对比差异具有统计学意义(P<0.05,P<0.01)。结论血清BNP和hsCRP测定可以作为临床上判断心力衰竭程度的一个参考指标,对评估心衰患者的病情和临床疗效一定的价值。 Objective To observe the changes of blood - serum high sensitivity C - reactive protein, BNP level, and study the association between high sensitivity C - reactive protein, blood - serum BNP level and congestive heart failure patients. Methods The blood - serum BNP and high sensitivi- ty C -reactive protein concentration in 50 patients with congestive heart failure and 45 controls were determined and contrasted. Results The blood -serum BNP and high sensitivity C -reactive protein levels in congestive heart failure patients was significantly higher than that of the controls (P 〈 0.05, P 〈 0.01 ). And with the increase of degree of congestive heart failure, the blood - serum BNP and high sensitivity C -reactive protein levels gradually increased. Conclusions The assay of the blood - serum BNP and high sensitivity C -reactive protein concentration is one reference index in judgement of the degree of congestive heart failure,and play an important role in the classification of cardiac function and clinical curative effect.
出处 《医药论坛杂志》 2011年第11期42-44,共3页 Journal of Medical Forum
关键词 B型钠利尿肽 高敏C反应蛋白 心衰 Brain natriuretic peptide High sensitivity C -reactive protein Congestive heart failure
  • 相关文献

参考文献11

  • 1Maisel AS, Koon J, Krishnaswamy P. Utility of B - natri- uretic peptideas a rapid point of care test for screening patients undergoin eehocardiography to determine left ventricular dysfunction[J].Am Heart J ,2001,141 ( 3 ) : 367 -374.
  • 2Verma S, Yeh ET. C -reactive protein and atherothrom- bosis beyond a biomarker an actual partaker of lesion from ation[ J]. Am 3 physiol Regul Integr Comp physiol, 2003,285 (5) : 1253-1256.
  • 3马海涛,吴翼伟,章斌.血浆利钠肽水平与心功能状态的关系[J].中国现代医学杂志,2002,12(20):4-6. 被引量:28
  • 4Koglin J, Pe vaI1U S, Schwaiblmair M, et al. Role of brain natruretie peptide in risk stratification of patients with congestive heart failure [ J ]. JACC, 2001,38 ( 7 ) : 1934.
  • 5尹芝兰,赵水平.充血性心力衰竭患者血清C-反应蛋白的变化及辛伐他汀的干预作用[J].中国医师杂志,2003,5(9):1225-1226. 被引量:79
  • 6Devaraj S, Singh U ,Jialal L. The evolving role C - reac- tive protein in atherothrombosis [ J ]. Clin Chem, 2009, 55 ( 2 ) : 229-238.
  • 7Shen J, Ordovas JM. Impact of genetic and environmen- tal factors on hsCRP concentrations and response to therapeutic agents [ J ]. Clin Chem, 2009,55 ( 2 ) : 256- 264.
  • 8Ridker PM, Danielson E, Fonseca AH. Rosuvastatin to prevent vascular events in men and women with elevated C - reactive protein [ J ]. N Engl J Med,2008,359 ( 21 ) : 2195-2207.
  • 9Li JJ, Ren Y, Chen KJ,et al. Impact of C -Reactive Protein on In -Stent: Restenosis. A Meta -Analysis [ J ]. Tex Heart Inst J, 2010,37 (1) :49-57.
  • 10Mattace - Raso FU, Verwoert GC, Hofman A, et al. Inflammation and incident - isolated systolic hypertension in older adults : the Rotterdam study [ J ]. J Hypertens, 2010,28 (5) :892-895.

二级参考文献14

  • 1Jianhui Zhu, Quyyumi AA, Norman JE, et al, Effects of total pathogen burden on coronary artery disease risk and C - reactive protein levels[J] .Am J Cardiol,2000,85 : 140 - 146.
  • 2Wolf MG,Zasmeta G, Homykewycz S, et al. Plasma levels of C - reactive prorein after coronary stent implantation[J] .Eur Heart J,2000,21:1152 - 1158.
  • 3Lenine B, Kalman J, Mayer L, et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure[J]. N Eng J Med, 1990,323:236- 241.
  • 4Gabay C, Kushner I. Actue - phase proteins and other systemic responses to inflammation[J]. N Eng Med, 1999,340:448 - 454.
  • 5Tataru MC,Heinrich J,Junker R,et al.C - reactive protein and the severity of atherosclerosis in myocardial infarction patients with stable angina pectoris[J]. Eur Heart J,2000,21 : 1000.
  • 6Albert MA, Staggers J, Chew P, et al. Investigators. The pravastatin inflammation CRP evaluation ( PRINCE ) : rationale and design [ J ]. Am Heart J,2001,141(6) :893 - 898.
  • 7Ridker PM, Rifai N, Clearfield M, et ,ak. Measurement - C - reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events[ J], N Engl J Med, 2001,344(26) : 1959 - 1965.
  • 8Bustos C, Hemandez- Presa MA, Ortego M, et al. HMG- COA reductase inhibition by atorvastatin reduces neointial inflammation in a rabbit model of atherosclerosis[J] .J AM Coll Cardiol, 1998,32(7) :2057 - 2064.
  • 9Maeda K,Tsutamoto T, Wada A, et al. High levels of plasma brain natriuretic peptide and interleukin - 6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol, 2000;36 (5):1581~1593
  • 10Cargill RI, Barr CS, Coutie WJ, et al. C-type natriuretic peptide levels in corpulmonale and in congestive heart failure. Thorax, 1994;49(12): 1247~1249

共引文献105

同被引文献41

引证文献4

二级引证文献39

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部